Date Title Description PDF
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download

Pages

Date Title Description PDF
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

Date Title Description PDF
08 Nov 2016 Información sobre resultados ROVI releases the presentation related to the nine-month period ended 30 September 2016 results Download
08 Nov 2016 Información sobre resultados (2) ROVI releases the press release related to the nine-month period ended 30 September 2016 results Download
08 Nov 2016 Otros sobre Gobierno Corporativo The Company informs about the agreement of the Board of Directors with regards to the appointment of the Accounts Auditor Download
04 Oct 2016 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the third quarter of 2016 Download
01 Aug 2016 Acuerdos estratégicos con terceros ROVI announces the marketing agreement of Mysimba in Spain Download

Pages